This database contains 1063 studies, archived under the term: "female"
Click here to filter this large number of results.
Continuous positive airway pressure deepens sleep in patients with Alzheimer’s disease and obstructive sleep apnea
Cooke, Jana R.,
Ancoli-Israel, Sonia,
Liu, Lianqi,
Loredo, Jose S.,
Natarajan, Loki,
Palmer, Barton S.,
He, Feng,
Corey-Bloom, Jody
Objective: Patients with Alzheimer’s disease (AD) and obstructive sleep apnea (OSA) experience disrupted sleep. This study examined the effect of continuous positive airway pressure (CPAP) on sleep parameters in AD patients with OSA.; Methods: A randomized placebo-controlled trial of 3 weeks of therapeutic CPAP (tCPAP) vs. 3 weeks placebo CPAP (pCPAP) followed by 3 weeks […]
Treatment of the symptoms of Huntington’s disease: preliminary results comparing aripiprazole and tetrabenazine
Brusa, Livia,
Orlacchio, Antonio,
Moschella, Vincenzo,
Iani, Cesare,
Bernardi, Giorgio,
Mercuri, Nicola Biagio
Aripiprazole (AP), a dopamine (DA) D(2) receptor partial agonist, has recently been used to reduce schizophrenic symptoms, while tetrabenazine (TBZ), a DA depletor, has been used to treat hyperkinesias in Huntington’s disease (HD). The aim of this study is to define the role of AP on chorea, motor performance, and functional disability, and to compare […]
An exploratory cluster randomized controlled trial of group exercise on mobility and depression in care home residents
Brittle, Nicola,
Patel, Smitaa,
Wright, Christine,
Baral, Sabrina,
Versfeld, Pam,
Sackley, Catherine
Objective: To investigate the feasibility, acceptability and potential efficacy of group exercise for residents in care homes.; Design: Exploratory cluster randomized controlled trial.; Setting: Five randomly selected care homes in South Birmingham, UK.; Participants: Fifty-six care home residents (mean age 84.5, 71% female), 39 (70%) with cognitive impairments.; Intervention: Two homes (n = 28) were […]
An open-label study of memantine treatment in 3 subtypes of frontotemporal lobar degeneration
Boxer, Adam L.,
Lipton, Anne M.,
Womack, Kyle,
Merrilees, Jennifer,
Neuhaus, John,
Pavlic, Danijela,
Gandhi, Anisha,
Red, Dana,
Martin-Cook, Kristen,
Svetlik, Doris,
Miller, Bruce L.
There are currently no Food and Drug Administration-approved treatments for frontotemporal lobar degeneration (FTLD). The objectives of this study were to explore the tolerability of memantine treatment in FTLD and to monitor for possible effects on behavior, cognition, and function. Forty-three individuals who met clinical criteria for FTLD [21 with frontotemporal dementia (FTD), 13 with […]
Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease
Beglinger, Leigh J.,
Adams, Williams H.,
Paulson, Henry,
Fiedorowicz, Jess G.,
Langbehn, Douglas R.,
Duff, Kevin,
Leserman, Anne,
Paulsen, Jane S.
Background: Cognitive symptoms are associated with functional disability in Huntington disease; yet, few controlled trials have examined cognitive treatments that could improve patient independence and quality of life. Atomoxetine is a norepinephrine reuptake inhibitor approved for treatment of attention-deficit/hyperactivity disorder.; Methods: Twenty participants with mild Huntington disease who complained of inattention were randomized to receive […]
Computer-based cognitive training for mild cognitive impairment: results from a pilot randomized, controlled trial
Barnes, Deborah E.,
Yaffe, Kristine,
Belfor, Nataliya,
Jagust, William J.,
DeCarli, Charles,
Reed, Bruce R.,
Kramer, Joel H.
We performed a pilot randomized, controlled trial of intensive, computer-based cognitive training in 47 subjects with mild cognitive impairment. The intervention group performed exercises specifically designed to improve auditory processing speed and accuracy for 100 min/d, 5 d/wk for 6 weeks; the control group performed more passive computer activities (reading, listening, visuospatial game) for similar […]
Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer’s disease: a 3-year follow-up longitudinal study
Angelucci, Francesco,
Bernardini, Sergio,
Gravina, Paolo,
Bellincampi, Lorenza,
Trequattrini, Alberto,
Di Iulio, Fulvia,
Vanni, Diego,
Federici, Giorgio,
Caltagirone, Carlo,
Bossù, Paola,
Spalletta, Gianfranco
Although the etiology of psychotic symptoms (hallucinations and delusions) in Alzheimer’s disease is still not known, alterations in serotonergic neurotransmission have been proposed. In a 3-year follow-up study, we evaluated the association of serotonin (5-HT) receptor 5-HT2a 102T/C polymorphism (allelic variants CC, CT and TT) with psychotic symptom severity and response to treatment with atypical […]
Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
Alvarez, X. Anton,
Sampedro, Carolina,
Cacabelos, Ramon,
Linares, Carlos,
Aleixandre, Manuel,
García-Fantini, Manuel,
Moessler, Herbert
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]